Abeona Therapeutics Inc. Share Price Today: Live Updates & Key Insights

Abeona Therapeutics Inc. share price today is $7.2839, up 4.93%. The stock opened at $6.99 against the previous close of $6.9, with an intraday high of $7.3 and low of $6.99.

Abeona Therapeutics Inc. Share Price Chart

Abeona Therapeutics Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Abeona Therapeutics Inc. Share Price Performance

$7.2839 0.0493(4.93%) ABEO at 10 Aug 2026 05:40 PM Biotechnology
Lowest Today 6.99
Highest Today 7.3
Today’s Open 6.99
Prev. Close 6.9
52 Week High 7.54
52 Week Low 4.00
Day’s Range: Low 6.99 High 7.3
52-Week Range: Low 4.00 High 7.54
1 day return -
1 Week return +13.31
1 month return +1.68
3 month return +23.25
6 month return +40.75
1 year return +14.93
3 year return +141.16
5 year return -77.03
10 year return -

Abeona Therapeutics Inc. Institutional Holdings

Nantahala Capital Management, LLC 8.80

BlackRock Inc 5.61

AIGH Capital Management, LLC 5.44

Cable Car Capital LLC 5.28

Suvretta Capital Management, LLC 4.70

Vanguard Capital Management, LLC 3.80

Vanguard Morn Total Stk Mkt Idx Investor 2.68

Propel Bio Management LLC 2.33

Kennedy Capital Management Inc 2.22

Geode Capital Management, LLC 2.12

iShares Russell 2000 ETF 2.09

The Goldman Sachs Group Inc 1.98

State Street Corp 1.68

NAN FUNG TRINITY (HK) Ltd 1.68

Awm Investment Company Inc 1.41

683 Capital Management LLC 1.35

Kennedy Micro Cap 1.35

Stonepine Capital Management Llc 1.31

SILVERARC CAPITAL MANAGEMENT, LLC 1.14

J. Goldman & Co LP 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.10

Diametric Capital, LP 1.07

Balyasny Asset Management LLC 1.03

Citigroup Inc 0.92

Fidelity Small Cap Index 0.82

iShares Russell 2000 Value ETF 0.71

Kennedy Micro Cap Opportunities 0.67

Russell 2000 Equity Index Fund B 0.50

Russell 2000 Index Non-Lendable Fund 0.50

Simplify Propel Opportunities ETF 0.48

Fidelity Extended Market Index 0.46

State St Russell Sm/Mid Cp® Indx SL Cl I 0.46

Vanguard Russell 2000 ETF 0.44

State St Russell Sm Cap® Idx SL Cl I 0.28

iShares Micro-Cap ETF 0.26

Extended Equity Market Fund B 0.25

Extended Equity Market Fund E 0.25

Blackrock Extended Mkt Fund CF 0.25

Fidelity Enhanced Small Cap Core ETF 0.22

BlackRock Extended Equity Market Fund K 0.21

Abeona Therapeutics Inc. Market Status

Strong Buy: 5

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Abeona Therapeutics Inc. Fundamentals

Market Cap 392.49 M

PB Ratio 2.5246

PE Ratio 7.2632

Enterprise Value 220.81 M

Total Assets 219.57 M

Volume 1396870

Abeona Therapeutics Inc. Company Financials

Annual Revenue FY23:3568000 3.6M, FY22:1414000 1.4M, FY21:3000000 3.0M, FY20:10000000 10.0M, FY19:0 0.0M

Annual Profit FY23:1863000 1.9M, FY22:964000 1.0M, FY21:3000000 3.0M, FY20:10000000 10.0M, FY19:-48566000 -48.6M

Annual Net worth FY23:-44718000 -44.7M, FY22:-31809000 -31.8M, FY21:-88606000 -88.6M, FY20:-88349000 -88.3M, FY19:-76682000 -76.7M

Quarterly Revenue Q1/2026:8720000 8.7M, Q3/2025:0 0.0M, Q2/2025:400000 0.4M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:5155000 5.2M, Q3/2025:-488000 -0.5M, Q2/2025:300000 0.3M, Q1/2025:-815000 -0.8M, Q3/2024:0 0.0M

Quarterly Net worth Q1/2026:-17075000 -17.1M, Q3/2025:-5161000 -5.2M, Q2/2025:108833000 108.8M, Q1/2025:-12029000 -12.0M, Q3/2024:-30269000 -30.3M

About Abeona Therapeutics Inc. & investment objective

Company Information Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Organisation Biotechnology

Employees 226

Industry Biotechnology

CEO Dr. Vishwas Seshadri M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Abeona Therapeutics Inc. FAQs

What is the share price of Abeona Therapeutics Inc. today?

The current share price of Abeona Therapeutics Inc. is $7.2839.

Can I buy Abeona Therapeutics Inc. shares in India?

Yes, Indian investors can buy Abeona Therapeutics Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Abeona Therapeutics Inc. shares in India?

You can easily invest in Abeona Therapeutics Inc. shares from India by:

Can I buy fractional shares of Abeona Therapeutics Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Abeona Therapeutics Inc.?

Abeona Therapeutics Inc. has a market cap of $392.49 M.

In which sector does Abeona Therapeutics Inc. belong?

Abeona Therapeutics Inc. operates in the Biotechnology sector.

What documents are required to invest in Abeona Therapeutics Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Abeona Therapeutics Inc.?

The PE ratio of Abeona Therapeutics Inc. is 7.26 and the PB ratio is 2.52.